ANTH:OTC-Anthera Pharmaceuticals, Inc (USD)

COMMON STOCK | Biotechnology | OTC

Last Closing Price

USD 0.07

Change

0.00 (0.00)%

Market Cap

USD 0.62M

Volume

0.04M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-05-09 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NONOF Novo Nordisk A/S

N/A

USD173.26B 25.36 2.88
CSLLY CSL Limited

N/A

USD97.28B 36.94 21.59
CMXHF CSL Limited

N/A

USD97.28B 36.55 21.59
GNMSF Genmab A/S

N/A

USD24.33B 32.55 3.06
SBHMY Sino Biopharmaceutical Limited

N/A

USD19.33B 45.25 2.70
SBMFF Sino Biopharmaceutical Limited

N/A

USD19.33B 46.09 2.70
UCBJF UCB SA

N/A

USD17.48B 21.54 14.56
UCBJY UCB SA

N/A

USD17.48B 20.69 14.56
PPTDF PeptiDream Inc

N/A

USD5.58B 140.76 0.71
AKBLF ALK-Abelló A/S

N/A

USD4.86B 392.60 13.19

ETFs Containing ANTH

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 153.09% 82% B- 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 153.09% 82% B- 85% B
Trailing 12 Months  
Capital Gain 248.00% 76% C 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 248.00% 76% C 79% C+
Trailing 5 Years  
Capital Gain -99.75% 1% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.75% 1% F 1% F
Average Annual (5 Year Horizon)  
Capital Gain -50.93% 1% F N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -50.93% 1% F N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 70.73% 56% F 39% F
Risk Adjusted Return -72.00% 8% F 5% F
Market Capitalization 0.62M 17% F 13% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 0.11 95% A 91% A-
Price / Cash Flow Ratio -0.02 22% F 55% F
EV/EBITDA 0.21 85% B 77% C+
Management Effectiveness  
Return on Equity -568.85% 10% F 3% F
Return on Invested Capital -1,044.65% 3% F 1% F
Return on Assets -141.96% 28% F 8% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 2.09 41% F 30% F
Short Percent 10.45% 15% F 18% F
Beta 2.02 17% F 19% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.